<DOC>
	<DOC>NCT00098059</DOC>
	<brief_summary>This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed.</brief_summary>
	<brief_title>Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>History or laboratory evidence of herpes simplex infection Clinical evidence or suspicion of herpes simplex infection Patients unable to swallow Concomitant use of probenecid Positive pregnancy test Additional protocoldefined inclusion/exclusion criteria may apply. For detailed information on eligibility, please contact the study center nearest to you or call the following numbers: 18627783544 or 14349513228</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>herpes simplex</keyword>
	<keyword>cold sores</keyword>
	<keyword>fever blisters</keyword>
	<keyword>children</keyword>
	<keyword>Famvir</keyword>
	<keyword>famciclovir</keyword>
</DOC>